These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3189 related articles for article (PubMed ID: 29033130)

  • 1. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
    Riaz N; Havel JJ; Makarov V; Desrichard A; Urba WJ; Sims JS; Hodi FS; Martín-Algarra S; Mandal R; Sharfman WH; Bhatia S; Hwu WJ; Gajewski TF; Slingluff CL; Chowell D; Kendall SM; Chang H; Shah R; Kuo F; Morris LGT; Sidhom JW; Schneck JP; Horak CE; Weinhold N; Chan TA
    Cell; 2017 Nov; 171(4):934-949.e16. PubMed ID: 29033130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
    Yusko E; Vignali M; Wilson RK; Mardis ER; Hodi FS; Horak C; Chang H; Woods DM; Robins H; Weber J
    Cancer Immunol Res; 2019 Mar; 7(3):458-465. PubMed ID: 30635271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
    Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.
    Trujillo JA; Luke JJ; Zha Y; Segal JP; Ritterhouse LL; Spranger S; Matijevich K; Gajewski TF
    J Immunother Cancer; 2019 Nov; 7(1):295. PubMed ID: 31703593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune checkpoint‑targeted cancer immunotherapies].
    Swatler J; Kozłowska E
    Postepy Hig Med Dosw (Online); 2016 Jan; 70():25-42. PubMed ID: 26864062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in immunotherapy for melanoma.
    Redman JM; Gibney GT; Atkins MB
    BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Byrne EH; Fisher DE
    Cancer; 2017 Jun; 123(S11):2143-2153. PubMed ID: 28543699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hallmarks of response to immune checkpoint blockade.
    Cogdill AP; Andrews MC; Wargo JA
    Br J Cancer; 2017 Jun; 117(1):1-7. PubMed ID: 28524159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.
    Alban TJ; Riaz N; Parthasarathy P; Makarov V; Kendall S; Yoo SK; Shah R; Weinhold N; Srivastava R; Ma X; Krishna C; Mok JY; van Esch WJE; Garon E; Akerley W; Creelan B; Aanur N; Chowell D; Geese WJ; Rizvi NA; Chan TA
    Nat Med; 2024 Nov; 30(11):3209-3222. PubMed ID: 39349627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 160.